Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease.
Location: United States, Ohio, Cleveland
Employees: 11-50
Total raised: $35.7M
Founded date: 2007
Investors 2
| Date | Name | Website |
| - | North Coas... | northcoast... |
| - | New Scienc... | newscience... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.05.2015 | - | $13.5M | - |
| 16.07.2012 | Series B | $22.2M | - |
Mentions in press and media 22
| Date | Title | Description |
| 25.10.2021 | Juventas Cell Therapy closes a $63M funding round as it eyes a big push for blood cancer hopeful | Juventas has grabbed a $63 million series C to advance its CASI Pharmaceuticals-partnered drug CNCT19. Sponsored by IPM.AI Optimizing Commercial and Patient Outcomes for Rare Diseases with AI, ML and RWD Learn how Kyowa Kirin partnered with... |
| 18.11.2020 | CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T) | |
| 13.05.2015 | Juventas Therapeutics Raises $13.5M | Juventas Therapeutics, Inc., a Cleveland, OH-based clinical-stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular diseases, secured $13.5m in financing. Green Cross Holdings and Posco Ca... |
| 13.05.2015 | Cleveland Clinic spinout Juventas Therapeutics raises $13.5M for cardiovascular gene therapy | Juventas has studied JVS-100 in a number of cardiovascular indications, including advanced chronic heart failure, late stage peripheral artery disease and critical limb ischemia. It also shows promise in refractory angina, heart attack, mus... |
| 12.05.2015 | Juventas Therapeutics Lands $13.5M | CLEVELAND, OH, Juventas Therapeutics today announced that the company has secured $13.5 million in financing. >> Click here for more funding data on Juventas Therapeutics >> To export Juventas Therapeutics funding data to PD... |
| 19.05.2014 | Juventas Therapeutics Data Demonstrates Significant Structural, Clinically Meaningful Benefit in Patients with Advanced Heart Failure | STOP-HF Trial of JVS-100 in Patients with Symptomatic Ischemic Cardiomyopathy Presented as Late Breaker at European Society of Cardiology- Heart Failure Congress CLEVELAND & ATHENS, Greece–(BUSINESS WIRE)–May 19, 2014– Juventas Therapeu... |
| 16.07.2012 | Juventas Therapeutics Closes $22.2M Series B Financing | Juventas Therapeutics, a Cleveland, OH-based clinical-stage regenerative medicine company, has closed a $22.2m Series B financing. The round was co-led by Triathlon Medical Venture Partners and New Science Ventures, with participation from ... |
| 16.07.2012 | Juventas Therapeutics Raises $22.2M Series B | CLEVELAND, OH, Clinical-stage regenerative medicine company, announced today that it has closed a $22.2 million Series B financing. >> Click here for more funding data on Juventas Therapeutics >> To export Juventas Therapeut... |
| 24.05.2011 | Juventas’ stem cell therapy shows promise in phase 1 study | Four months after treatment, heart failure patients involved in the study showed improvements in their performance in a walking test, as well as better scores on the Minnesota Living with Heart Failure Questionnaire, according to a statemen... |
| 27.04.2011 | Urologix touts five-year study on enlarged prostrate treatment | Research roundup | Urologix Inc. (NSDQ:ULGX) is heralding the results of a long-term study on its enlarged prostate treatment device. Data from a study published in The Journal of Urology show that the Minneapolis-based medical device manufacturer’s Cooled Th... |
Show more